Clinical trial · Interventional
Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VP301 in Patients With Relapsed or Refractory Multiple Myeloma, Lymphoma, or Solid Tumors
NCT05698888CI-TRIAL-00069745terminatedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Sponsor Decision
Summary
Brief summary (as posted)
This study will test the safety, tolerability, and pharmacokinetics of VP301 in patients with relapsed or refractory multiple myeloma, lymphoma, or solid tumors.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
| Solid Tumors, Adult | Adult Solid Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| VP301 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- VP301 (Dose Escalation)
- description
- Eligible patients will receive VP301 administered as an IV infusion weekly for 6 weeks then every 2 weeks. Patients will be enrolled into escalating dose levels during the Dose Escalation period of the study.
- interventionNames
- Drug: VP301
- type
- EXPERIMENTAL
- label
- VP301 (Dose Expansion)
- description
- Eligible patients will receive VP301 administered as an IV infusion weekly for 6 weeks then every 2 weeks. Patients will receive the maximum tolerated dose or recommended phase 2 dose during the Dose Expansion period of the study.
- interventionNames
- Drug: VP301
Primary outcomes (2)
- measure
- Occurrence of General Toxicity
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologic diagnosis of a refractory solid tumor, refractory myeloma or lymphoma with measurable or evaluable disease * Patients must have progressed following all therapies of known, potential clinical benefit, or for whom treatments of known clinical benefit are contraindicated. * Adequate kidney, liver, and hematologic function * Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2 Exclusion Criteria: * Active brain metastases and history of leptomeningeal metastases. * Myeloma patients with plasmacytoma as only measurable disease * Non-secretory myeloma * Patients with advanced metastatic, symptomatic, visceral spread who are at risk of life-threatening complications * Active or chronic, uncontrolled bacterial, viral, or fungal infection(s) * Abnormal ECG * Has clinically significant cardiovascular disease * Additional active malignancy that may confound the assessment of the study endpoints * Pregnancy or lactation * Known seropositivity for HIV (human immunodeficiency virus) or active hepatitis B or hepatitis C
References
Publications (0)
Data not yet available
No reference posted for this study.